Table 2.
Demographics and comorbidities in colistin and ceftolozane/tazobactam treated patient groups.
| Variable | CMS group (n = 33) | C/T group (n = 18) | p value |
|---|---|---|---|
| Demographic factors and severity of illness | |||
| Age (years) | 67 (62–72) | 60 (46–72) | 0.07a |
| Male sex | 23 (69.7%) | 11 (61.1%) | 0.53b |
| APACHE II | 27 (21–34) | 25 (20–31) | 0.34a |
| SOFA | 6 (5–10) | 7 (6–9) | 0.66a |
| Preexisting condition | |||
| CCI | 4 (3–6) | 3 (1–6) | 0.11a |
| Hypertension | 23 (69.7%) | 10 (55.5%) | 0.31b |
| Heart failure | 17 (51.5%) | 6 (33.3%) | 0.21b |
| Cerebrovascular disease | 6 (18.1%) | 2 (11.1%) | 0.69b |
| Peripheral arterial disease | 7 (21.2%) | 2 (11.1%) | 0.46b |
| Lung disease | 8 (24.2%) | 7 (38.8%) | 0.27b |
| Kidney disease | 1 (3.0%) | 0 (0%) | 1.00b |
| Liver disease | 2 (6.0%) | 1 (5.5%) | 1.00b |
| Peptic ulcer disease | 4 (12.1%) | 4 (22.2%) | 0.43b |
| Diabetes mellitus | 6 (18.1%) | 4 (22.2%) | 0.72b |
| Solid-organ tumor | 4 (12.1%) | 2 (11.1%) | 1.00b |
| Leukaemia | 3 (9.0%) | 0 (0%) | 0.54b |
| Corticosteroids | 3 (9.0%) | 3 (16.6%) | 0.65b |
| Other immunosuppressive therapy | 2 (6.0%) | 2 (11.1%) | 0.60b |
| Neutropenia | 3 (9.0%) | 1 (5.5%) | 1.00b |
| Smoking | 11 (33.3%) | 7 (38.8%) | 0.69b |
APACHE II Acute Physiology and Chronic Health Evaluation II score, CCI Charlson Comorbidity Index, CMS colistimethate sodium, C/T ceftolozane/tazobactam, SOFA Sequential Organ Failure Assessment score.
aMann–Whitney U test.
bχ2 test or Fisher’s exact test.